Take part in a paid clinical trial

Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is a progressive liver condition linked to obesity, insulin resistance, and high cholesterol. It can lead to serious complications such as progressive liver disease and liver cancer.

Current treatment options are limited and often rely on lifestyle changes like diet and exercise. While some medications exist, they don’t work for everyone, highlighting the need for new therapies.

This clinical trial is evaluating a potential new injectable medication designed to activate two important pathways in the body that help regulate metabolism, reduce liver fat, and improve insulin sensitivity. These pathways are known to play a role in managing metabolic disorders and liver inflammation.

We are conducting a clinical trial to evaluate a potential new antibiotic in healthy adult volunteers. This study aims to assess the safety, tolerability, and how the body processes this medication. 

The investigational treatment is being developed to combat antimicrobial resistance (AMR) by targeting dangerous bacteria. 

The investigational treatment is being developed as a potential future therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). This is the first step in evaluating the treatment’s safety and how it behaves in the body before testing its effectiveness in patients with these conditions. 

The investigational treatment is being developed as a potential future therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD). This is the first step in evaluating the treatment’s safety and how it behaves in the body before testing its effectiveness in patients with these conditions.